ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: BiondVax Pharmaceuticals Ltd. Sponsored ADR (BVXV) Report Updated: Aug 19, 2017 | Print This Page

Get more stock ratings by Louis Navellier

BiondVax Pharmaceuticals Ltd. Sponsored ADR (BVXV)

Rating: Strong Buy Volatility: Moderate
Total Grade: A Industry: Pharmaceuticals
Competitors: PAHC,ASMB,SNY,MYOK

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: A down no change
Last Week: A same upgrade
Two Weeks Ago: B up no change
service keys

BiondVax Pharmaceuticals Ltd. Sponsored ADR© quotemedia

Company Profile

BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, develops and manufactures universal influenza vaccine. It offers M-001, a universal flu vaccine that provides multi-season and multi-strain protection against various human influenza virus strains, including seasonal and pandemic. The company was founded in 2003 and is based in Ness Ziona, Israel with an additional office in the United States.